超声引导射频消融治疗甲状腺微小癌疗效分析

目的 探讨超声引导射频消融（RFA）治疗甲状腺微小癌患者的疗效。方法 收集18例（22枚）甲状腺微小癌患者RFA治疗资料，所有患者于RFA前和RFA后即刻、1、3、6、12、24个月分别接受二维超声、CEUS和甲状腺功能检查，评估消融后疗效。结果 18例中，结节一次性完全消融率达100%，均未发生喉返神经损伤、出血等严重并发症。RFA前结节平均体积（0.08±0.07）ml，RFA后平均随访（14.21±8.72）个月，最后一次随访时微小癌平均体积为（0.004±0.020）ml，与消融后即刻相比，结节体积平均缩小（1.52±0.64）ml。随访期间，共20枚结节基本消失，且颈部未发现可疑转移性淋巴结。RFA前后所有患者的甲状腺功能指标均在正常参考值范围。结论 超声引导RFA治疗甲状腺微小癌具有安全、疗效好等优点，可有效保留甲状腺功能。

Analysis of therapeutic effect of ultrasound-guided radiofrequency ablation for thyroid microcarcinoma

Objective To observe the therapeutic effect of ultrasound-guided radiofrequency ablation (RFA) in the treatment of thyroid microcarcinoma. Methods Totally 18 patients with 22 thyroid nodules received RFA were enrolled. Routine ultrasound, CEUS and thyroid function test were performed in all patients to evaluate the therapeutic efficacy immediately after RFA, 1 month, 3 months, 6 months, 12 months and 24 months after RFA. Results The nodular complete ablation rate was 100%, and no recurrent laryngeal nerve injury, bleeding nor other serious complications occurred. Before RFA, the mean volume of thyroid microcarcinoma was (0.08±0.07)ml. The average follow-up period after radiofrequency ablation was (14.21±8.72) months, and the mean volume of microcarcinoma at the last follow-up was (0.004±0.020)ml. Compared with that immediately after ablation, the mean volume of lesions reduced to (1.52±0.64)ml. During the follow-up period, a total of 20 nodules almost disappeared, and no suspicious cervical metastatic lymph nodes were found. Before and after RFA, all patients had normal reference range of thyroid function. Conclusion Ultrasound-guided RFA is a safe method for thyroid microcarcinoma with good curative effect, contributing to effectively preserve thyroid function.